Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rimsza

Showing results (121-130 of 203) with videos related to

Pageof 21
Sort By:
Leukemia & Lymphoma|August 1, 2002
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levelsM G Mainwaring, L M Rimsza, S F Chen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 2025
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of OriginGeffen Kleinstern, Dennis P Robinson, Lisa M Rimsza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomabOliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell LymphomaSantiago Demajo, Robert Albero, Guillem Clot, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2015
Survival of human lymphoma cells requires B-cell receptor engagement by self-antigensRyan M Young, Tianyi Wu, Roland Schmitz, et al.
Blood|June 12, 2008
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPLisa M Rimsza, Michael L Leblanc, Joseph M Unger, et al.
Blood Advances|October 15, 2021
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangementsLeonie Frauenfeld, Natalia Castrejon-de-Anta, Joan Enric Ramis-Zaldivar, et al.
Genes, Chromosomes & Cancer|September 8, 2007
Frequent occurrence of deletions in primary mediastinal B-cell lymphomaLindsey R Kimm, Ronald J deLeeuw, Kerry J Savage, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Related F-box proteins control cell death in Caenorhabditis elegans and human lymphomaMichael Chiorazzi, Lixin Rui, Yandan Yang, et al.
Pageof 21

Showing results (121-130 of 203) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|August 1, 2002
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levelsM G Mainwaring, L M Rimsza, S F Chen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 2025
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of OriginGeffen Kleinstern, Dennis P Robinson, Lisa M Rimsza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomabOliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell LymphomaSantiago Demajo, Robert Albero, Guillem Clot, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2015
Survival of human lymphoma cells requires B-cell receptor engagement by self-antigensRyan M Young, Tianyi Wu, Roland Schmitz, et al.
Blood|June 12, 2008
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPLisa M Rimsza, Michael L Leblanc, Joseph M Unger, et al.
Blood Advances|October 15, 2021
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangementsLeonie Frauenfeld, Natalia Castrejon-de-Anta, Joan Enric Ramis-Zaldivar, et al.
Genes, Chromosomes & Cancer|September 8, 2007
Frequent occurrence of deletions in primary mediastinal B-cell lymphomaLindsey R Kimm, Ronald J deLeeuw, Kerry J Savage, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Related F-box proteins control cell death in Caenorhabditis elegans and human lymphomaMichael Chiorazzi, Lixin Rui, Yandan Yang, et al.
Pageof 21